Lately, PARP inhibitors, a new class of drugs that interfere with the DNA damaging repairing abilities of tumor cells, have shed new light on the expanded treatment options for ovarian cancer patients (34, 35). This evidence concerns the gene PARP1 and ovarian cancer.